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Purpose: The migratory neural crest cell population makes a significant contribution to the anterior segment structures
of the eye. Consequently, several anterior segment dysgenesis phenotypes are associated with mutations in genes expressed
during neural crest development. The forkhead box D3 (FOXD3) gene encodes a forkhead transcription factor that plays
an important role in neural crest specification in vertebrates and therefore may be involved in human eye disease.
Methods: We screened 310 probands with developmental ocular conditions for variations in FOXD3.
Results: Six nonsynonymous FOXD3 variants were identified. Four of these changes, c.47C>T (p.Thr16Met), c.359C>T
(p.Pro120Leu), c.517A>C (p.Asn173His), and c.818_829dup (p.Arg273_Gly276dup), affected conserved regions and
were observed primarily in probands with aniridia or Peters anomaly; out of these four variants, one, p.Arg273_Gly276dup,
was not detected in control populations and two, p.Pro120Leu and p.Asn173His, were statistically enriched in cases with
aniridia or Peters anomaly. The p.Arg273_Gly276dup variant was seen in a proband with aniridia as well as two additional
unrelated probands affected with anophthalmia or congenital cataracts. The p.Asn173His variant affects Helix 2 of the
DNA-binding domain and was observed in two unrelated patients with Peters anomaly or aniridia; in both cases, one
parent carried the same allele.
Conclusions: FOXD3 variants increase the risk of anterior segment dysgenesis phenotypes in humans. The p.Asn173His
mutation affects a residue in the forkhead domain that is 100% conserved among vertebrate orthologs and is predicted to
participate in protein–protein interactions. Its phenotypic effects may be modulated by transcriptional cofactors which
have yet to be identified.
Abnormal development of the anterior eye leads to a wide
spectrum of ocular malformations, which increase glaucoma
risk [1]. During embryogenesis, migratory neural crest cells
make a significant contribution to the anterior ocular
structures, including the cornea, iris and ciliary body [2,3].
Several anterior segment dysgenesis conditions, such as
Axenfeld-Rieger and Peters anomalies, are associated with
mutations in genes that regulate neural crest cell development
(reviewed in [4,5]). The forkhead box D3 (FOXD3) gene
encodes a forkhead transcription factor with a role in
segregation of the neural crest lineage from the
neuroepithelium and maintenance of neural crest cells in an
undifferentiated state during early stages of patterning by
repressing melanogenesis and thus allowing other neural crest
derivatives to develop [reviewed in 6]. Mutations in at least
12 forkhead box genes have been implicated in Mendelian
disorders: FOXC1 (OMIM 601090), FOXC2 (OMIM
602402), FOXE1 (OMIM 602617), FOXE3 (OMIM 601094),
FOXF1 (OMIM 601089), FOXG1 (OMIM 164874), FOXI1
Correspondence to: Elena V. Semina, C3520, Translational and
Biomedical Research Center, Medical College of Wisconsin, 8701
Watertown Plank Road, Milwaukee, WI, 53226-0509; Phone: (414)
955-4996; FAX: (414) 955-6329; email: esemina@mcw.edu
(OMIM 601093), FOXL2 (OMIM 605597), FOXN1 (OMIM
600838), FOXP1 (OMIM 605515), FOXP2 (OMIM
605317), and FOXP3 (OMIM 300292) [7].
The structure and function of FOXD3 are conserved
among vertebrates. In mice, Foxd3 transcripts are detected in
blastocyst stage (E6.5) embryos, throughout the epiblast and
in the extraembryonic region [8]. During mid-gestation (E9.5-
E10.5), Foxd3 is expressed in pre-migratory and migratory
neural crest cells in the head and tail regions, but expression
decreases in differentiated cells derived from the neural crest
[9]. While mice with a heterozygous Foxd3 deletion appear
healthy and normal, Foxd3−/− embryos die shortly after
implantation, around E6.5, and show a correlated loss of
embryonic (epiblast) cells and expansion of extraembryonic
tissues [8]. Conditional deletion of the Foxd3 coding region
in neural crest cells in Foxd3flox/–;Wnt1-Cre mice results in
neonatal lethality [10]. By E16.5, embryos with neural crest-
specific loss of Foxd3 have nervous system defects and
variable craniofacial malformations, including cleft face and
palate, and a subgroup have cardiac defects. In zebrafish,
foxd3 is first expressed during gastrulation, at the neural plate
border, and in the tailbud mesoderm, somites, and floor plate
[11]. While foxd3 expression is observed in premigratory
neural crest cells, its expression is downregulated as these
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cells emerge from the dorsal neural tube and differentiate.
Some foxd3 expression, however, persists transiently in a
subset of migrating neural crest cells in the somites and
peripheral glia [12,13]. Zebrafish deficient in foxd3 exhibit
cardiac and craniofacial defects and embryonic lethality
[13-15]. In addition, foxd3 has been shown to negatively
regulate the expression of microphthalmia-associated
transcription factor a (mitfa), which controls cell fate
specification of melanocytes in zebrafish; thus, foxd3
prevents neural crest precursors from differentiating into
melanophores, instead promoting iridophore specification
[16,17]. In chick and Xenopus, over- or ectopic expression of
FoxD3 interferes with neural crest differentiation [9,18-20].
Taken together, these data indicate that FOXD3 is required for
development of neural crest derivatives and that its actions are
dosage-sensitive.
No mutations have been reported in the human FOXD3
coding region. However, one study reported an association
between vitiligo, an autoimmune skin condition characterized
by progressive patchy depigmentation, and the chromosome
1p31 region that includes FOXD3, in a multi-generation
family with 13 affected individuals [21]. Sequencing of the
coding and promoter regions of FOXD3 and eight other genes
identified a heterozygous −639G>T substitution in the
FOXD3 promoter which co-segregated with the disease
phenotype in the family and was not seen in matched controls
[22]. This substitution increases FOXD3 transcription, which
may interfere with melanoblast differentiation, creating an
autoantigen and predisposing to vitiligo.
Given the importance of neural crest cells in the
formation of the anterior eye, and the example of FOXC1 and
FOXE3 mutations in human anterior segment disease
[23-27], we screened a cohort of subjects with ocular
anomalies for FOXD3 mutations. We identified four variants
affecting conserved regions in five patients with aniridia or
Peters anomaly.
METHODS
Patient samples: Human subjects research approval was
obtained from Institutional Review Boards at the Children’s
Hospital of Wisconsin, the University of Michigan, and Paris
7 University Hospitals. Written informed consent was
provided by all participants and/or their legal guardian, as
appropriate. Blood or buccal samples were collected from
probands and available family members. DNA was extracted
by standard methods.
Screening of human DNA samples: The full coding region of
FOXD3 was amplified by PCR using four sets of primers
(Appendix 1). Thermal cycling conditions for sets 1–3 were
performed as follows: 94 °C for 2 min, followed by 38 cycles
of 94 °C for 1 min, 60 °C for 1 min, 72 °C for 1.5 min, and a
final elongation at 72 °C for 10 min. Thermal cycling
conditions for set 4 were performed as follows: 94 °C for 5
min, followed by 38 cycles of 94 °C for 45 s, 60 °C for 45 s,
72 °C for 1 min, and a final elongation at 72 °C for 7 min.
Bidirectional sequencing of the PCR products was performed
using ABI 3730XL sequencer and protocols (Applied
Biosystems/Life Technologies, Carlsbad, CA). Sequencing
reactions were performed using the same forward and reverse
primers used for amplification, with one exception: set 4 PCR
product was sequenced using internal set 4b (Appendix 1).
The sequences were analyzed manually and with Mutation
Surveyor software (SoftGenetics, State College, PA).
Available family members were also screened for FOXD3
coding changes.
Normal controls included DNA samples from 190
Caucasian, 95 African-American, 95 Asian, and 96 Hispanic
individuals. Caucasian controls were obtained from the
European Collection of Cell Culture (Salisbury, UK), and
other control samples were obtained from the Coriell Institute
(Camden, NJ). Additional comparisons were performed using
the NHLBI Exome Variant Server (EVS) [28] and the Single
Nucleotide Polymorphism (SNP) database [29]. Allele
frequencies were calculated based on the number of
chromosomes with sufficient quality scores (in-house data)
and/or coverage (EVS data) for each region, then compared
between cases and pooled controls by the Fisher's exact test
[30].
Paired box gene 6 (PAX6) [31,32] screening was
performed using eight sets of primers (Appendix 1) and the
following cycling conditions: 94 °C for 5 min, followed by 38
cycles of 94 °C for 45 s, 60 °C for 45 s, 72 °C for 1 min, and
a final elongation at 72 °C for 7 min. PCR reactions were
performed using standard buffers (5 Prime Inc., Gaithersburg,
MD) and conditions with DMSO (5%) and betaine (20%) in
each reaction. Bidirectional sequencing of the PCR products
and sequence analysis was performed as described above.
PAX6 copy number was determined using TaqMan (Applied
Biosystems/Life Technologies) probes Hs00255072_cn
(overlapping intron 1 and exon 2) and Hs02661628_cn
(within the last exon).
Previous genetic screens in the ocular disease cohort
included FOXE3 (forkhead box E3), CYP1B1 (cytochrome
P4501B1), B3GALTL (beta-1,3-galactosyltransferase-like),
PITX2 (pituitary paired-like homeodomain transcription
factor 2), FOXC1 (forkhead box C1), and PITX3 (paired-like
homeodomain 3) [33-37].
RESULTS
Screening the FOXD3 coding region: DNA samples from 310
unrelated patients with developmental eye anomalies were
screened for variations in the FOXD3 coding region by PCR
sequencing. The primary diagnoses include 79 cases with
anophthalmia/microphthalmia, 63 with aniridia, 57 with
Peters anomaly, 44 with congenital cataracts, 36 with anterior
segment dysgenesis (including Axenfeld-Rieger anomaly) or
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isolated glaucoma, and 31 with other ocular disorders. Six
nonsynonymous variants were identified (Table 1). Four of
these changes affected conserved regions and were identified
primarily in probands with aniridia or Peters anomaly; out of
these four variants, one was not detected in control
populations and two were statistically enriched in cases
compared to controls.
The first variant, c.47C>T, is predicted to cause a
p.Thr16Met substitution in the NH2-terminus of the FOXD3
protein (Table 1, Figure 1, and Figure 2). This heterozygous
variant was seen in Patient 1, a six-month-old Caucasian male
with left Peters anomaly with iridocorneal adhesions, right
congenital cataract with anterior synechiae, bilateral iris and
lens colobomas, abnormal iris and corneal vascularization,
persistent hyperplastic primary vitreous, and foveal
hypoplasia. There were no systemic anomalies. The mother
was reported to have had a ‘lazy eye’ as a child, which was
treated by patching, and currently has moderate
anisometropia. The patient’s father and brother are
unaffected. The mother also carried the p.Thr16Met allele
(Figure 1). The methionine substitution affects a highly
conserved domain near the NH2-terminus of FOXD3 and the
position is occupied by threonine in all known vertebrate
orthologs (Figure 2). The p.Thr16Met variant was not
observed in 456 in-house controls, but is heterozygous in 8 of
5,276 individuals in the EVS. The frequency of the
p.Thr16Met allele shows no significant difference between
cases and controls based on Fisher’s exact test (1/232 for
Peters anomaly/aniridia versus 8/11464 control
chromosomes, p=0.165).
The second variant, c.359C>T, is predicted to cause a
proline to leucine substitution at position 120 in the NH2-
terminal region of FOXD3, 18 residues before the forkhead
domain (Table 1, Figure 1 and Figure 2). This variant was
detected in Patient 2 with aniridia. The gender, ethnicity and
family history are not known. The substitution affects a region
with moderate evolutionary conservation; the proline at this
position is conserved among mammals, but it is replaced by
serine and tyrosine in chick and zebrafish orthologs,
respectively (Figure 2). The p.Pro120Leu variant was
observed in 1 sample among 455 in-house controls, and was
not observed among the EVS individuals (n=4,489). Based on
Fisher’s exact test, the frequency of this variant is statistically
increased in aniridia and Peters anomaly cases (1/232 versus
1/9888 chromosomes, p=0.045).
The third variant, c.517A>C, is predicted to cause a
p.Asn173His substitution within the forkhead domain (Table
1, Figure 1, and Figure 2) and was identified in two unrelated
patients in our cohort. Patient 3 is a 10-year-old Caucasian
female with unilateral Peters anomaly (iridocorneal
adhesion), exotropia, and horizontal nystagmus. She also has
a mild hearing deficit in the left ear, minimally posteriorly
rotated ears (left>right), a broad nasal bridge, and mild
clinodactyly. The patient’s mother is unaffected, while her
father was reported to have had a ‘lazy eye’ treated by
patching as a child, but no other clinical details were available.
Patient 3 has one brother and one sister, who were reported to
be unaffected but were unavailable for screening. The father
also carries the p.Asn173His change (Figure 1). Patient 4 is a
10-year-old Caucasian male with aniridia. Both of his parents
are reported to be unaffected and there are no siblings. The
patient’s mother also carries the p.Asn173His allele (Figure
1). The substitution affects an amino acid in the forkhead
domain that is 100% conserved among vertebrate FOXD3
orthologs (Figure 2). The p.Asn173His variant was not
observed in 473 in-house controls but was detected 1 of 5,379
individuals in the EVS. The p.Asn173His allele frequency is
statistically increased in aniridia and Peters anomaly cases
(2/240 versus 1/11,704 control chromosomes, p=0.001).
The fourth variant is a 12-base-pair in-frame duplication,
c.818_829dup, which is predicted to cause a tandem
duplication (p.Arg273_Gly276dup) of four amino acids (Arg-
Pro-Tyr-Gly) near the COOH-terminus, downstream of the
forkhead domain (Table 1, Figure 1 and Figure 2). This was
detected in Patient 5 with aniridia. The gender, ethnicity, and
family history are not known. The duplication affects a
moderately conserved region of FOXD3. The
p.Arg273_Gly276dup variant was not observed in 455 in-
house controls or the SNP database (insertions and deletions
are not recorded in the EVS so the presence/absence of the
duplication in this population could not be determined).
Interestingly, the c.818_829dup duplication was also
identified in two additional unrelated ocular patients in our
cohort, a Caucasian male with isolated anophthalmia and a
female with isolated bilateral congenital cataracts. Even
though this variant was not found in any control samples in
our study or the SNP database, the difference was not
statistically significant based on Fisher’s exact test (1/238
versus 0/910 chromosomes, p=0.207 for aniridia/ Peters
anomaly patients; 3/610 versus 0/910 chromosomes, p=0.064
for all ocular cases).
Two other nonsynonymous variants identified included
c.262_273del (p.Ala88_Gly91del) and c.286G>T
(p.Val96Leu; Table 1). Both of these variants affect
nonconserved regions and residues, and were observed at a
similar frequency in cases and controls with p values of 1 and
0.597, respectively.
Since PAX6 mutations account for the majority of aniridia
cases, and have also been reported in Peters anomaly,
iridocorneal adhesion and foveal hypoplasia phenotypes [31,
32], we carefully examined the PAX6 coding region and copy
number in Patients 1–5, and found no alterations (data not
shown).
DISCUSSION
FOXD3 plays an important role in the specification and
development of the neural crest cells that make a significant
Molecular Vision 2012; 18:1740-1749 <http://www.molvis.org/molvis/v18/a179> © 2012 Molecular Vision
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Figure 1. Identification of FOXD3 sequence variants in Peters anomaly and aniridia. Pedigrees and sequence chromatograms for variants
identified in Patients 1–5 (A-D). The mutations are indicated (red arrows).
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contribution to human ocular structures. Analysis of FOXD3
mutations in human ocular disease is the first step toward
characterizing its potential involvement in human eye
development and pathology. Here, we report four FOXD3
Figure 2. Position and interspecies conservation of FOXD3 variants. Schematic of the FOXD3 protein showing the forkhead domain (shaded)
and positions of the amino acid variants affecting conserved regions; variants that showed a statistically significant association with the patient
population (see text) are marked with an asterisk (A). Amino acid alignments of vertebrate FOXD3 proteins for the corresponding regions
(B).
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variants identified primarily in patients with Peters anomaly
and aniridia and affecting conserved regions of the FOXD3
protein. Peters anomaly is a developmental defect
characterized by central corneal opacity, defects in the
posterior layers of the cornea, and variable lenticulo-corneal
and irido-corneal adhesions [38,39]; aniridia is a panocular
disorder in which the iris is absent or severely reduced, with
additional findings including corneal opacification,
glaucoma, cataracts and foveal hypoplasia [31,32,40]. No
enrichment for FOXD3 variants was observed in other ocular
phenotypes: while the p.Arg273_Gly276dup mutation was
detected in one case each of anophthalmia and congenital
cataracts, no other significant variants in FOXD3 were
identified in the sizable population screened with these
phenotypes (n=123).
In all five Peters anomaly/aniridia families reported here,
the clinical phenotype was only noted in the proband and
mutations in PAX6, the primary aniridia gene [31,32] were
excluded; in two families, the parent carrying the FOXD3
variant had a ‘lazy eye’ (ambylopia) during childhood. All
four variants involve conserved positions in the FOXD3
protein; variants p.Thr16Met and p.Asn173His alter residues
that are 100% identical among vertebrates. Two variants,
p.Asn173His and p.Pro120Leu, showed a statistically
significant increase in allele frequency in the Peters anomaly/
aniridia subgroup in comparison to controls and one allele,
p.Arg273_Gly276dup, was not detected in our control
samples or reported by others, but was found in two additional
ocular cases with anophthalmia and cataract phenotypes in
this study.
The p.Asn173His substitution is of particular interest
since it was observed in two unrelated probands with Peters
anomaly/aniridia and affects the DNA-binding domain. The
presence of this variant in one normal control chromosome
(out of 11,702) is consistent with the reduced penetrance, or
subclinical expressivity, seen in the unaffected carrier parents.
Similarly, incomplete penetrance and variable expressivity
have been observed in families with heterozygous mutations
in orthodenticle homeobox 2 (OTX2) [41] or bone
morphogenetic protein 4 (BMP4) [42], which are associated
with anophthalmia/microphthalmia or severe anterior
segment dysgenesis.
Additional studies are required to identify the functional
consequences of the reported variations. The p.Thr16Met,
p.Pro120Leu and p.Arg273_Gly276dup variants involve
NH2- or COOH-terminal regions of FOXD3 which have not
yet been assigned any specific function but are, in general,
believed to play a role in the modulation of FOXD3 activity
in different tissues/processes through interactions with other
proteins. The p.Asn173His variant involves the forkhead
domain of FOXD3 which is responsible for its interaction with
DNA. Although asparagine 173 is not predicted to contact
DNA, it may interact with other proteins, modulating DNA
binding affinity/specificity through allosteric effects. The
NMR structure of the rat Foxd3/Genesis forkhead domain has
been determined, both in the free state and in a Foxd3-DNA
complex [43-45]. In the unbound state, the FOXD3 forkhead
domain contains four α helices, three β strands, and two wing
motifs. The fourth helix (H4) is unique to FOXD3. It is located
between helices 2 (H2) and 3 (H3), and replaces a random coil
segment in other FOX proteins. Upon DNA binding, FOXD3
undergoes a conformational change that perturbs the wing
domains, decreases overall flexibility, and induces a fifth
helical fold (H5), which is absent in the free state [43]. The
junction between H2 and H3 is thought to play a role in DNA-
binding specificity [46]. H3 makes direct contact with the
DNA major groove, while wing domain W2 interacts with the
minor groove [46,47]. The asparagine 173 is located near the
carboxyl end of helix 2 (H2) in the forkhead DNA-binding
domain. The p.Asn173His substitution introduces an
ionizable and possibly positively charged side chain to this
region. Though the exact consequences of this change are
unknown, the p.Asn173His substitution may disrupt a protein
interaction or alternatively recruit an erroneous protein to the
site. These effects may be tissue specific and require the
presence of particular cofactors that are yet to be determined.
Several previously reported mutations affect the H2 helix
of other forkhead proteins. The recessive mouse mutation
dyl (dysgenic lens) results from two concurrent amino acid
substitutions in the Foxe3 gene, p.Phe93Leu and p.Phe98Ser.
Mice homozygous for both mutations have small eyes with a
fused lens and cornea, absent secondary lens fibers, and
cataracts [24]. Some heterozygous dyl-/+ mice (40%) have a
milder corneal and lens phenotype, including corneal opacity,
keratolenticular adhesions and cataracts [25]. Phe93 is located
in helix H2, and Phe98 is located in the interhelical region
between H2 and H3. In human FOXC1, a phenylalanine–to-
serine substitution (p.Phe112Ser) in the first residue after
helix H2 was discovered in a large family with heterogeneous
anterior segment defects [26]. The mutation decreased
transcriptional activation in an in vitro cotransfection assay,
but did not detectably impair DNA-binding [27].
In summary, we report the identification of four
FOXD3 variants in five human patients with the anterior
segment dysgenesis phenotypes Peters anomaly and aniridia.
These findings are consistent with the role of Foxd3 in
specification of the neural crest emerging from animal model
studies [10,13-15]. Although enriched in the Peters anomaly/
aniridia cohort, the presence of these rare FOXD3 variants in
unaffected family members and controls suggests that
additional genetic, environmental or stochastic factors may be
required for expression of the disease phenotype. The
secondary factor(s) may involve proteins that interact directly
with FOXD3 or modulate its activity. Future biochemical and
genetic studies of the FOXD3 pathway may identify cofactors
as new candidate genes for eye disease and clarify the
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contribution of FOXD3 mutations to human eye
malformations.
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Appendix 1. Oligonucleotides used for PCR and sequencing of the
FOXD3 and PAX6 genes.
To access the data, click or select the words “Appendix
1.” This will initiate the download of a compressed (pdf)
archive that contains the file.
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